- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04027517
A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.
A Multi-center, Randomized, Open-label, Active-controlled, Parallel-group, Phase III Study to Compare the Efficacy and Safety of JTZ-951 With Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Receiving Maintenance Hemodialysis.
JTZ-951 is a currently being developed as a treatment for renal anemia. This study aims to evaluate the efficacy and safety of JTZ-951 following a switch from erythropoiesis-stimulating agent (ESA) in Korean subjects receiving HemoDialysis with renal anemia.
This study is a Phase III, open, active-controlled, parallel-group, multi-center study.
The total duration of the study will be 30 weeks including screening, treatment and follow-up.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- SMG-SNU Boramae Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Korean patients aged ≥ 19 years at the time of consent
- Patients receiving hemodialysis (including hemodiafiltration) consistently three times a week for at least 12 weeks before Scr Visit 1
- Patients with TSAT (Transferrin saturation) *2 > 20% or ferritin > 75 ng/mL at Scr Visit 1*1
- Patients being treated with ESAs for as least 4 weeks before Scr Visit 1.
- Patients receiving ESAs at protocol specified dose regimen (i.e., frequency and dose)
- Patients who have received the same ESA received in most recent week before Scr Visit 1 as during the period between Scr Visit 1 and the day before Week 0 at the same total dose and dosing frequency a week*4.
- Patients with pre-dialysis Hb levels measured after the maximum interdialytic interval at Scr Visit 1 and Scr Visit 2 (2 weeks after Scr Visit 1) of ≥ 9.5 g/dL and < 12.0 g/dL and a difference (in absolute value) between Scr Visit 1 and Scr Visit 2 of ≤1.0 g/dL
Exclusion Criteria:
- Patients with poorly controlled hypertension
- Patients with severe hepatobiliary disease
- Patients with congestive heart failure (NYHA Class III or more) or unstable angina
- Patients who have developed myocardial infarction, cerebral infarction (excluding asymptomatic cerebral infarction), or venous thromboembolism (pulmonary embolism or deep vein thrombosis) during the period between 24 weeks before Scr Visit 1 and Week 0.
- Patients who will undergo an ophthalmological procedure (photocoagulation therapy or vitreous surgery) for the treatment of diabetic retinopathy, diabetic macular edema, or age- related macular degeneration during the period between Scr Visit 1 and the end of the study
- Patients who have undergone erythrocyte transfusion during the period between 12 weeks before Scr Visit 1 and Week 0.
- Patients who have received protein anabolic hormones, testosterone enanthate, or mepitiostane during the period between 12 weeks before Scr Visit 1 and Week 0.
- Patients with severe hyperparathyroidism
- Patients with severe infection, systemic blood disorder (e.g., myelodysplastic syndrome, aplastic anemia, abnormal hemoglobin disease), or hemolytic anemia, or patients with anemia caused by obvious bleeding lesions (e.g., gastrointestinal hemorrhage)
- Patients who are suspected to have anemia caused by noninfectious chronic inflammatory disease (e.g., connective tissue disease)
- Patients with malignancy (including hematological malignancy) or previous history of malignancy during the period between 5 years before Scr Visit 1 and Week 0
- Patients with previous history of a serious drug allergy such as anaphylactic shock or a hypersensitivity to DA
- Patients with current or previous history of drug dependence or alcohol dependence
- Patients who have received another investigational product or have received treatment with an investigational device, or have participated in clinical research involving intervention (medical action beyond the scope of ordinary medical practice intended for research purposes) and received treatment within 12 weeks before Scr Visit 1
- Patients who have previously participated in a clinical study of JTZ-951 and received the investigational product
- Patients who are pregnant, lactating, or may be pregnant (the possibility of pregnancy cannot be ruled out by the PI or the SI based on the results of pregnancy test at Scr Visit 1)
- Female patients of childbearing potential who have not agreed to use appropriate contraception methods (medically accepted contraceptive methods: surgical sterilization, intrauterine device, condom, diaphragm, etc.) from the time of signing of informed consent to the end of the study, or male patients who have not agreed to use appropriate contraception methods from the start of study treatment to the end of the study.
- Other patients who, in the judgment of the PI or the SI, are ineligible for the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JTZ-951
Oral doses once daily
|
Oral tablet
Other Names:
|
Active Comparator: Darbepoetin Alfa
Intravenous doses of Darbepoetin Alfa administered once weekly
|
Intravenous administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in mean Hb level change during the evaluation period from baseline (evaluation period - baseline) between study arm and control arm
Time Frame: baseline and Week 20 to 24
|
Hb level during the evaluation period is the mean of the Hb levels at Week 20, Week 22 and End of Treatment (Week 24 or at discontinuation).
|
baseline and Week 20 to 24
|
Difference in mean Hb level between study arm and control arm during the evaluation period
Time Frame: baseline and Week 20 to 24
|
Hb level during the evaluation period is the mean of the Hb levels at Week 20, Week 22 and End of Treatment (Week 24 or at discontinuation).
|
baseline and Week 20 to 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with Hb level within the range of baseline ± 1.0 g/dL at Week 4
Time Frame: Week4
|
Week4
|
Proportion of subjects with mean Hb level of ≥10.0 g/dL and <12.0 g/dL during the evaluation period
Time Frame: Week 20, 22, 24
|
Week 20, 22, 24
|
Hb level at each Visit
Time Frame: Week 2, 4, 8, 12, 16, 20, 22, 24
|
Week 2, 4, 8, 12, 16, 20, 22, 24
|
Change from baseline in Hb level at each Visit
Time Frame: Week 0, 2, 4, 8, 12, 16, 20, 22, 24
|
Week 0, 2, 4, 8, 12, 16, 20, 22, 24
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Lee, JW Pharmaceutical
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JWP-JTZ-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia of Chronic Kidney Disease
-
Medical University of ViennaCompletedAnemia of Chronic Kidney DiseaseAustria
-
Dong-A ST Co., Ltd.UnknownAnemia of Chronic Kidney DiseaseTurkey
-
Chong Kun Dang PharmaceuticalCompletedAnemia of Chronic Kidney Disease
-
Rufaida MazahirCompletedAnemia of Chronic Kidney DiseaseIndia
-
Bio Sidus SAUnknownAnemia of Chronic Kidney DiseaseArgentina, Paraguay
-
Helwan UniversityCompletedAnemia of Chronic Kidney Disease | Chronic Renal Failure | Chronic Renal Failure AnemiaEgypt
-
Xiamen Amoytop Biotech Co., Ltd.First Affiliated Hospital of Zhejiang UniversityCompletedRenal Anemia of Chronic Kidney DiseaseChina
-
Shenzhen Second People's HospitalRecruiting
-
Hoffmann-La RocheCompletedRenal Anemia of Chronic Kidney DiseaseCroatia
Clinical Trials on JTZ-951
-
Akros Pharma Inc.CompletedAnemia of Chronic Kidney DiseaseUnited States
-
Akros Pharma Inc.CompletedAnemia of Chronic Kidney DiseaseUnited States
-
Akros Pharma Inc.CompletedAnemia in Chronic Kidney DiseaseUnited States
-
Akros Pharma Inc.CompletedAnemia of Chronic Kidney DiseaseUnited States
-
AbbVieCompletedParkinson's Disease (PD)United States
-
AVEO Pharmaceuticals, Inc.CompletedCarcinoma, Non-Small-Cell LungUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompleted
-
Emory UniversityAVEO Pharmaceuticals, Inc.Terminated